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Chlamydiae are obligate intracellular
bacteria that grow in eukaryotic cells and
cause a wide spectrum of human disease
(Table). Species were grouped according to
their biologic and biochemical properties and
a greater than 95% homology in their 16s
ribosomal RNA sequences (1). Molecular
analyses led to the reclassification of some
Chlamydia psittaci strains as Chlamydia
pneumoniae,  a human pathogen, and Chla-
mydia pecorum, a pathogen of ruminants.
Given the diverse host range of C. psittaci
strains, more reclassification within this
species may be likely.
The oldest reported disease associated
with  C. trachomatis infection is trachoma, a
sequela of ocular infection. This disease was
described in China and in the Ebers papyrus
in Egypt thousands of years ago and
continues to be a major cause of preventable
blindness, with an estimated 500 million
cases of active trachoma worldwide (seven
million include blindness from conjunctival
scarring and eyelid deformities [2]). In the
last two decades, genital chlamydial infection
has been identified as a major public health
problem because of the recognition that
chlamydial infection is associated with
disease syndromes such as nongonococcal
urethritis, mucopurulent cervicitis, pelvic
inflammatory disease (PID), ectopic
pregnancy, and tubal infertility. The World
Health Organization estimated 89 million
new cases of genital chlamydial infections
worldwide in 1995 (3). In the United States,
each year an estimated four million new
cases occur and 50,000  women become
infertile as a result of infection (4).
C. psittaci infection, acquired through
respiratory droplet transmission of
chlamydiae from infected birds, has been
considered for many years an occupational
hazard for employees of pet shops and
poultry processing plants (5). Sources of
human C. psittaci infection other than
infected birds have been identified and may
The recognition of genital chlamydial infection as an important public health
problem was made first by the recognition of its role in acute clinical syndromes, as
well as in serious reproductive and ocular complications, and secondly by our
awareness of its prevalence when diagnostic tests became widely accessible.  The
recent availability of effective single dose oral antimicrobial therapy and sensitive
molecular amplification tests that allow the use of noninvasive specimens for
diagnosis and screening is expected to have a major impact in reducing the
prevalence of disease in the next decade. Clinical manifestations associated with
Chlamydia pneumoniae infection continue to emerge beyond respiratory illness. In
particular, its association with atherosclerosis deserves further investigation.
Chlamydia pecorum, a pathogen of ruminants, was recently recognized as a new
species. The continued application of molecular techniques will likely elucidate an
expanding role for chlamydiae in human and animal diseases, delineate the
phylogenetic relationships among chlamydial species and within the eubacteria
domain, and provide tools for detection and control of chlamydial infections.Emerging Infectious Diseases Vol. 2, No. 4—October-December 1996 308
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Table. Spectrum of human diseases caused by Chlamydiae
Species Acute Diseases Sequelae/Chronic Diseases
C. trachomatis
Serovars A-C conjunctivitis trachoma
Serovars D-K urethritis proctitis, epididymo-orchitis, Reiter’s Syndrome
cervicitis pelvic inflammatory disease, ectopic pregnancy, tubal
infertility, Fitz-Hugh Curtis Syndrome
ophthalmia neonatorum
neonatal pneumonia
LGV serovars lymphogranuloma venereum
C. pneumoniae pharyngitis ?cardiovascular disease
sinusitis ?asthma
bronchitis
community-acquired pneumonia
C. psittaci
parrot atypical pneumonia
canaries hepatic and renal
pigeons dysfunction
turkeys endocarditis
ducks
chickens
cats conjunctivitis
ewes abortion
be more common than currently recognized.
Detection of C. psittaci in household cats and
breeding catteries illustrates the expanding
number of chlamydial diseases in animals
that are transmissible to humans (6,7).
C. pneumoniae is a human pathogen
recognized as an important cause of
respiratory illness (8). Approximately 40% to
60% of adult populations around the world
have antibodies to C. pneumoniae, which
suggests that the infection is extraordinarily
prevalent, and reinfection is common.
Current interest centers on the emerging
role of C. pneumoniae infection in the
pathogenesis of atherosclerosis and asthma.
Biology of Chlamydiae: An Update
Chlamydiae have a unique biphasic life
cycle with dimorphic forms that are function-
ally and morphologically distinct. An extra-
cellular form, the elementary body (EB), is
infectious but metabolically inactive. Once
endocytosed, the EB differentiates into a
larger pleomorphic form called the reticulate
body (RB), which replicates by binary fission.
The precise mechanism by which EBs attach
and gain entry into the host cell is unknown.
Recent work suggests that chlamydiae
employ a molecular mimic of heparan sulfate
to attach to glycosaminoglycan (GAG)
receptors on eukaryotic cell surfaces (9).
GAG appears to form a trimolecular complex
with the host cell since (EB) infectivity is
inhibited by the addition of heparan or
heparan sulfate to culture, and pretreatment
of EBs with heparan sulfate lyase abolishes
EB infectivity. The mechanism of endocytic
uptake remains unclear. Once inside the
host cell, chlamydiae reside in a membrane-
bound vacuole that can evade phagolysosomal
fusion. The endosome is transported to the
distal region of the Golgi apparatus and
incorporates host-derived sphingolipids into
the inclusion membrane (10,11). Thus it
appears that chlamydiae are able to
intercept host vesicular traffic bound for the
plasma membrane to sequester lipids and
possibly other host substances synthesized
in the Golgi. Subversion of host vesicular
traffic may represent a dual advantage for
chlamydiae in obtaining materials from the
host for its metabolism as well as in
modifying the inclusion membrane to evade
lysosomal fusion and immune detection.
Chlamydiae are considered energy para-
sites because they lack the enzymes of the
electron transport chain and thus require
adenosine triphosphate (ATP) and nutrientVol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 309
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resources from the host to fuel their
metabolism and replication. Chlamydiae are
incapable of de novo nucleotide biosynthesis
and are dependent on host nucleotide pools
(12). In spite of the successful selection of
various metabolic mutants of C. trachomatis,
progress in elucidating the host-parasite
metabolic relationship has been hampered
by multiple salvage metabolic pathways in
the host and the lack of a genetic shuttle
system for chlamydiae.
C. trachomatis
Epidemiology
Genital infections due to C. trachomatis
are the most common sexually transmitted
diseases in many industrialized countries (3).
Each year, an estimated four million new
cases occur in the United States and three
million in Europe. These infections present
unique problems for public health control
programs because 50 % to 70% of infections
in women (and perhaps men) are clinically
silent. Unrecognized and untreated, the
bacteria may remain infectious in the host
for months and be readily transmitted to sex
partners. Furthermore, most reported infec-
tions occur in the 15- to 24-year-old age
group. Young women with cervical chlamy-
dial infections are at risk for pelvic
inflammatory disease, which can lead to
long-term reproductive sequelae such as
chronic pelvic pain, ectopic pregnancy, and
tubal infertility. Babies born to infected
mothers are also at risk for conjunctivitis
and pneumonia. The annual direct and
indirect costs of genital chlamydial infec-
tions in the United States are estimated at
$2.4 billion (4).
Control programs emphasizing early
diagnosis, targeted screening, partner notifi-
cation, and effective treatment have led to a
slow decline in the incidence of genital
chlamydial infection in countries where
these programs have been implemented (13).
The true rate of decline may be higher than
the reported rate because of increased
sensitivity of laboratory testing and more
widespread screening. In women, screening
of chlamydial infection at the time of
Papanicolaou tests, prenatal visits, or
attendance at family planning or pregnancy
counseling clinics have been effective. In
asymptomatic men, who are less likely to
access care, asymptomatic infection is not
adequately addressed by current public
health programs.
In contrast to genital chlamydial infec-
tion, trachoma is a household disease that
has disappeared in many parts of the world
because of improved living conditions and
hygiene. In trachoma-endemic areas, severe
disease leading to scarring and blindness
may be the result of frequent reinfection or
persistent infection in those whose immune
system does not mount an adequate response
to clear the infection. For both ocular and
genital chlamydial infections, recent ad-
vances in diagnostic and screening technol-
ogy and single dose antimicrobial therapy
will likely have a significant impact on the
efficacy of disease control programs and the
opportunity for eventual disease eradication.
Laboratory Diagnosis
Since curative antibiotic therapy for
chlamydial infections is readily available
and inexpensive, early diagnosis is an
essential component of public health pro-
grams to control these infections. The goals
of early identification are to interrupt the
chain of transmission in the community and
to prevent long-term sequelae. Isolation of
the organism in cell culture had been the
traditional method for laboratory diagnosis
and has remained the method of choice for
medicolegal specimens because of its speci-
ficity. However, culture requires expensive
equipment, technical expertise, and strin-
gent transport conditions to preserve speci-
men viability; it also has a turnaround time
of 2 to 3 days. Hence, in many settings,
culture has been replaced by antigen-
detection methods, such as enzyme immu-
noassays (EIA) and direct fluorescence
assays (DFA), which have less demanding
transport requirements and can provide
results on the same day. EIAs are suitable
for public health laboratories serving large
geographic areas because specimens are
stable in transport under ambient conditions
and are inexpensive because they allow
specimens to be processed in batches by
automated equipment. Assays are typically
based on the capture of the chlamydialEmerging Infectious Diseases Vol. 2, No. 4—October-December 1996 310
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lipopolysaccharide (LPS) using monoclonal
or polyclonal antibodies linked to a solid-
phase support. Early problems with low
specificity because of cross-reactivity be-
tween the chlamydial LPS and that of other
gram-negative bacteria have been largely
overcome by confirmation with DFA or a
blocking antibody assay. With a lower
detection limit of 10,000 elementary bodies,
EIA lacks sensitivity as a screening assay,
especially for asymptomatic men (14,15).
Nucleic acid-based hybridization probe tests
offer higher specificity but no substantial
improvement on sensitivity (15). Nucleic
acid amplification tests based on polymerase
chain reaction (PCR), ligase chain reaction
(LCR), and transcription-mediated amplifi-
cation technology are now commercially
available. The precision of nucleic acid
hybridization and the rapid amplification of
a single gene target facilitated the design of
diagnostic tests with specificities in excess of
99% and lower detection limits of 1-10 EBs.
In addition, these tests offer all the
advantages of nonculture tests in terms of
ambient specimen transport, batching, auto-
mation, and rapid processing time of 4 hours.
Duplex testing for the simultaneous detec-
tion of chlamydial and gonococcal DNA from
a single specimen is also commercially
available in some countries.
A major advantage of the increased
sensitivity of these molecular amplification
tests is that noninvasive specimens, such as
urine, can be used for testing. The ease of
collection and the lack of sampling bias of
urine specimens make screening feasible in
settings outside physicians’ offices. PCR
assays on urethral or cervical swabs for the
laboratory diagnosis of genital chlamydial
infection in symptomatic men and women
show sensitivities of 89% to 100% and
specificities of 99% to 100% compared with
the traditional culture or PCR test, con-
firmed by a second PCR reaction targeting a
different gene (16-18). For urine specimens,
PCR assays show sensitivities of 87% to
100% for men and 92% for women and
specificities of 96% to 100% for men and 95%
for women (18-20). In a study of 447 women
with a prevalence of infection of 6%, the
sensitivity of urine LCR was 96% compared
with 56% for cervical swab culture, 78% for
cervical swab EIA, and 37% for urine EIA
(21). For men in the same study, the
sensitivity of urine LCR was 96% compared
with 68% for urine EIA, and 38% for urethral
swab culture. In a multicenter study of 2,132
women, cervical swab LCR showed a
sensitivity of 87% to 98% compared with a
sensitivity of 52% to 92% for culture (22). In
LCR studies, a true positive was defined as
culture positive or LCR positive confirmed
with DFA or another LCR assay with a
different DNA target. Thus it appears that
molecular amplification techniques for the
detection of C. trachomatis in urine speci-
mens from both men and women are a
substantial improvement over conventional
diagnostic and screening methods and will
provide an important tool for decreasing the
reservoir of infection, especially in asymp-
tomatic men.
In the diagnostic laboratory, molecular
techniques present different problems for
specimen handling and interpretation of
results than cell culture or antigen detection
(15). Inherent in the increased sensitivity of
these molecular techniques is the potential
for false-positive results due to cross
contamination between specimens, and run-
to-run contamination from equipment, re-
agents, and supplies. These problems can be
overcome by observing stringent rules for
specimen preparation (e.g., dedicated equip-
ment) and separating specimen processing
and reagent preparation areas to prevent
contamination. Enzymatic or photochemical
sterilization can be used to eliminate run-to-
run contamination. False-negative results
may be due to substances in specimens
inhibitory to enzymes used for amplification.
Known inhibitors include phosphate ions,
heparin, heme, crystals in the urine
specimens, and detergents used in specimen
processing. Internal controls are now com-
mercially available to detect false negatives.
Although molecular tests are more
expensive than EIA, cost-effectiveness stud-
ies should take into consideration the
benefits of averting the enormous costs of
long-term reproductive sequelae in women
with undetected infections, adverse preg-
nancy outcomes, and HIV infection. Targeted
screening of women to detect cervical
chlamydial infection decreases the incidenceVol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 311
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of symptomatic PID (23). Patients with
genital gonococcal or chlamydial infections
are also at increased risk for human
immunodeficiency virus (HIV) (24). Al-
though the risk for HIV may be lower in
patients with chlamydial infection than in
those with genital ulcer disease, the higher
prevalence of chlamydial infection in some
populations means that the population
attributable risk for HIV may be substan-
tially higher for chlamydia. Shortening the
duration of infectiousness by early diagnosis
and treatment could have a major impact on
risk reduction for HIV infection. A recent
study showed that strengthening sexually
transmitted disease control through educa-
tion, access to diagnosis, and treatment
reduced the incidence of HIV by 42% in study
communities in Tanzania over 2 years (25).
Treatment
Azithromycin prescribed as a single oral
1-g dose is equivalent to the traditional 7-
day regimen of doxycycline for treating
ocular and uncomplicated genital chlamydial
infections (26-28). Compared with conven-
tional therapy, azithromycin has excellent
pharmacokinetic characteristics, such as
increased bioavailability; lower incidence of
gastrointestinal tract side effects; and
increased concentration in mucus, macroph-
ages, and tissues with a half life of 5 to 7 days
(29). These characteristics allow for single
dosing, which alleviates the problem of
patient noncompliance with multiday regi-
mens. With single-dose therapy, the poten-
tial for reinfection due to earlier resumption
of sexual activity is a concern. At present,
there are limited data on the use of single-
dose therapy in adolescents, during preg-
nancy, and for syndromes such as PID,
cervicitis, and nongonococcal urethritis (30-
33). Studies are needed to determine if these
regimens achieve clinical and microbiologic
cure while preserving fertility and prevent-
ing further tissue damage to the upper
genital tract.
Although the higher cost of azithromycin
may be prohibitive for its use in resource-
limited settings, selective use in persons at
high risk or in those with a history of
noncompliance may prove cost-effective. The
cost of retreatment as a result of noncompli-
ance and the additional cost of contact
tracing can make single dose azithromycin
more cost-effective than doxycycline (34).
Pathogenesis
Interesting findings in three areas of C.
trachomatis pathogenesis further delineate
the complex bacteria-host relationship in
disease and may have implications for
vaccine design. These new observations
include the extensive but unexpected poly-
morphism of the major outer membrane
protein (MOMP), the evidence for genetic
susceptibility to disease, and the association
of antibody response to the 60 kDa heat
shock protein (CHSP60) with the develop-
ment of adverse sequelae following ocular
and genital infections.
Polymorphism of MOMP
The ecologic success of a pathogen is
determined in part by its ability to evade
host defenses. With C. trachomatis, MOMP
is a major target for protective host immune
responses, such as neutralizing antibodies
and possibly, protective T-cell responses
(35,36). The basis for MOMP antigenic
variation is allelic polymorphism at the omp-
1 locus, and immune selection appears to be
occurring in host populations frequently
exposed to C. trachomatis (37). Each variant
apparently only infects hosts lacking serovar-
specific immunity to that variant, and the
ecologic success of chlamydiae may be due to
their ability, under immune selection pres-
sure, to generate successive allelic variants
(36). DNA sequence analyses of isolates from
different populations show that most MOMP
variants are results of single amino acid
substitutions (37-39). Recombination of
sequences from MOMP during mixed infec-
tions may also have occurred. Recombinant
variants with mosaic sequences of MOMP
from different strains were especially fre-
quent in persons with high rates of infection.
MOMP variants were also more frequently
found in women with PID than in those with
lower genital tract infections, which sug-
gests a relationship between sequence
variation in MOMP and more invasive
disease (39). Clearly, the extensive polymor-
phism of MOMP, the tempo for variation, and
the mechanism of immune selection haveEmerging Infectious Diseases Vol. 2, No. 4—October-December 1996 312
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important implications for vaccine design
(35).
Genetic Susceptibility to Disease
HLA B27 has been associated with
Reiter’s syndrome following genital chlamy-
dial infection (40). Only a subset of infected
persons appear to have long-term complica-
tions after acute or repeated chlamydial
infections. In a study of 306 persons from
trachoma-endemic communities in the
Gambia, the HLA class I antigen HLA-A28
was significantly more common in case-
patients than in age-, sex-, and location-
matched controls (41). In particular, the
A*6802 allele was overrepresented among
case-patients. It may be that immunopathol-
ogy is associated with HLA-A*6802 re-
stricted cytotoxic T-lymphocyte responses.
The frequency of HLA class II alleles was
similar among cases and controls suggesting
that, if class II restricted T-cell responses
are important in immunopathology, they
were not targeted at single epitopes. No
individual HLA type was associated with
protection from scarring, which suggests
that multiple or complex T-cell responses
may be involved in protective immunity.
Susceptibility to chlamydial PID in a study
of sex workers in Nairobi, Kenya, has been
associated with a HLA class I allele, HLA A-
31 (42). Studies are needed to determine
whether susceptibility to silent PID, ectopic
pregnancy, and progression to tubal factor
infertility are associated with HLA class I
restricted immune responses.
Role of CHSP60 in Immunopathology
Antibody response to a 57 kDa chlamy-
dial protein was initially observed more
frequently in women with tubal infertility
than in controls (43). This protein was
subsequently identified as a heat shock
protein of the GroEL family of stress
proteins. The association between antibody
response to CHSP60 and PID, ectopic
pregnancy, tubal infertility, and trachoma
(44-48) has been documented. The risk
factors associated with CHSP60 antibody
response are similar to those for chlamydial
PID and include older age and chronic or
repeated infections. There appears to be
genetic restriction for the CHSP60 antibody
response. In a study of trachoma in the
Gambia, HLA DRB1*0701 was positively
correlated with CHSP60 response, while
DRB1*0301 and DQB1*0501 were negatively
associated (48). However, these alleles were
not associated with trachoma and may
reflect linkage disequilibrium between HLA
class II alleles and polymorphic markers for
other immune response genes.
At present, it remains unclear whether
antibody to CHSP60 is causally involved in
chlamydial immunopathogenesis or is merely
a marker of persistent chlamydial infection
(35). Both may be true. In cells persistently
infected with C. trachomatis, the expression
of CHSP60 is normal, while other antigens,
such as MOMP, are downregulated, thus
providing continued antigenic stimulation
for the CHSP60 antibody response observed
in persons with long-term sequelae (49). T-
cell responses to chlamydial antigens,
including CHSP60, were more depressed in
persons with trachoma than in those who
recovered from infection without sequelae
(50). Persons with trachoma or reproductive
sequelae have high levels of serum antibody
response to C. trachomatis. In guinea pigs
and in gene knock-out mice, both B- and T-
cell responses have been important in
immunity and resolution of infection (51,52).
Therefore, persons with long-term sequelae
may have predominantly Th
2 responses,
characterized by high levels of B-cell
response and inadequate T-cell responses
that may not clear the infection thus leading
to chronic inflammation. Immunopathology
may also be the result of a hit-and-run
mechanism in which immune response to
CHSP60 breaks self-tolerance to the human
HSP60 and leads to an autoimmune reaction
that results in tissue damage (35).
C. psittaci
Epidemiology
Human infections with C. psittaci are
caused by occupational exposure to infected
birds or household handling of nasal
discharge or fecal material from pet birds.
Birds can be healthy carriers of C. psittaci.
Increased shedding and susceptibility to
disease occur under conditions of stress suchVol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 313
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as shipping, crowding, starvation, or egg
laying. Person-to-person transmission is
rare but has been observed in outbreaks. In
the C. psittaci pandemic of 1929-30, infected
birds from Argentina were shipped to
different parts of the world causing out-
breaks of infection worldwide with death
rates of up to 40% (5). Since then C. psittaci
has been isolated from more than 130 species
of birds. Thus, all avian species, including
wild birds, should be regarded as potential
sources of zoonosis.
Reports of outbreaks of psittacosis in
duck and turkey processing plants show
that, in spite of availability of medicated
feed, diagnostic testing, and screening of
poultry,  C. psittaci infections continue to be
a public health concern (53,54). High rates of
chlamydial infection in household cats and
asymptomatic carriage of C. psittaci  in cats
from breeding catteries raise the possibility
that human C. psittaci infection from pets
other than birds may be underdiagnosed
(6,7,55,56). Studies of animal and cellular
tropism of various strains within the species
may give important clues to the pathogenesis
of C. psittaci infections.
Clinical Manifestations
Human infection caused by exposure to
infected birds or poultry is manifested as a
flulike illness characterized by fever, chills,
headache, and less frequently, cough,
myalgias, rash, arthralgia and joint swell-
ing, and atypical pneumonia in more severe
cases. The incubation period is 6 to 19 days.
Infections transmitted from ruminants are
rare, but placentitis, disseminated intravas-
cular coagulation, and spontaneous abortion
in women exposed to infected sheep during
lambing have been reported (56). Zoonoses
associated with exposure to ruminants are
characterized by multiorgan involvement
often resulting in hepatic and renal dysfunc-
tion and endocarditis. Human conjunctivitis,
glomerulonephritis, and endocarditis caused
by C. psittaci from infected cats and pigeons
have been reported (55).
Diagnosis and Treatment
Serodiagnosis has been the method of
choice for human C. psittaci infections
because culture is technically demanding
and represents an important biohazard. The
complement fixation assay is genus specific.
Its interpretations should depend on clinical
symptoms and patient history. The
microimmunofluorescence (MIF) assay can
detect species-specific IgM or IgG antibod-
ies. Antigen detection methods, such as EIA,
have been used, but they are based on the
capture of the genus-specific LPS. PCR
assays are not yet commercially available
but can offer lower detection limits of 10 EBs
or less (57,58). Molecular techniques not only
provide more sensitive and rapid diagnosis
than serology, but they also provide the
opportunity for fingerprinting strains. This
is particularly useful in outbreak investiga-
tions and for the confirmation of zoonotic
transmission from infected birds or animals.
The recommended treatment for C.
psittaci infection is 250 mg of tetracycline 4
times daily for 21 days. Although the death
rate is low, prolonged hospitalization may be
required. Protracted recovery and high
incidence of relapse have also been noted.
C. pneumoniae
Epidemiology
C. pneumoniae is a common cause of
acute respiratory tract infections and ac-
counts for 6% to 10% of community-acquired
pneumonia (8). Infection is usually mild or
asymptomatic but can be severe, especially
in the elderly, probably as a result of
underlying illness, impaired mucociliary
clearance, and immune senescence. Unlike
C. psittaci, C. pneumoniae is spread by
person-to-person transmission by respira-
tory droplet and has an incubation period of
7 to 21 days. Outbreaks of infection have
been reported in families, schools, military
barracks, and nursing homes. Coinfection
with viruses (e.g., influenza and respiratory
syncytial virus) and with bacteria has been
reported frequently. Seroepidemiologic stud-
ies show that most primary infections occur
during school age and the early teenage
years; among adults seroprevalence is 40% to
70%. Reinfections are common, and serum
antibodies do not appear to be protective.Emerging Infectious Diseases Vol. 2, No. 4—October-December 1996 314
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Laboratory Diagnosis
Accurate and rapid laboratory diagnostic
methods leading to improved patient care,
appropriate use of antimicrobial therapy,
and better understanding of the epidemiol-
ogy of this emerging pathogen (59,60) are
needed. Culture is highly specific but is
technically demanding often requiring mul-
tiple passages over a period of weeks to show
a positive result. C. pneumoniae has been
isolated from the nasopharynx of healthy
persons, but the rate of asymptomatic
carriage in a normal population is unknown
(61).
Antigen detection tests, such as EIA and
DFA, and molecular detection methods, such
as PCR assays, provide a rapid diagnosis
without stringent transport requirements.
Monoclonal antibodies specific for C.
pneumoniae  are now commercially available
for DFA and for culture confirmation (62).
PCR assays have lower detection limits of 10
to 100 EBs (57,58,63-65). The protocol
developed by Tong and Sillis amplifies a
target sequence conserved between C.
pneumoniae and C. psittaci and hence can
detect DNA from either pathogen in a single
assay (57). A nested PCR procedure is used to
differentiate between the C. pneumoniae
and C. psittaci amplicons. The protocol of
Rasmussen et al. amplifies a genus-specific
target, followed by species differentiation
using restriction enzyme digestion (58). The
development of multiplex PCR assays
containing primers specific for a panel of
respiratory pathogens will be useful.
The MIF assay is the standard method
used for chlamydia serology today. Ekman
compared the performance of the comple-
ment fixation (CF), LPS-based EIA, and MIF
tests for the serodiagnosis of C. pneumoniae
and  C. psittaci infections in an elderly
population and found that the CF test has a
sensitivity of 10% compared with 88% and
72% for MIF and EIA, respectively (66). IgM
antibodies were only detected in 11% of the
cases. IgM antibodies are rarely produced in
reinfections with C. pneumoniae. CF tests
may be useful in early initial infections as
LPS antibodies are produced early in
infection. Serodiagnosis may be made by
demonstrating a fourfold rise in CF or EIA
titer in paired sera taken a week apart,
compared with the 3 weeks or more that it
takes by MIF to demonstrate seroconversion.
Because reinfections are common and LPS-
based serologic tests are not useful in
reinfection, the MIF assay remains the most
useful and specific tool for the serodiagnosis
of respiratory infections due to C.
pneumoniae.
Treatment
The newer macrolides, clarithromycin
and azithromycin, with longer tissue half-
life and concentration in mucus and
macrophages and improved bioavailability
can potentially provide shorter and better-
tolerated regimens for the treatment of
respiratory infections due to C. pneumoniae
than doxycycline or erythromycin, which
have to be given for 2 to 3 weeks to avoid
relapse. They may also be preferred for
empiric therapy as they provide broader
coverage than erythromycin against etiologic
agents in community-acquired pneumonia.
The optimal duration of treatment for
respiratory infections due to C. pneumoniae
needs to be determined since studies with
documented microbiologic cure are limited,
and recurrence of infection is common (67).
Association with Atherosclerosis
The association of C. pneumoniae infec-
tion with coronary heart disease and acute
myocardial infarction was first made on the
basis of elevated IgG and IgA antibodies and
LPS containing immune complexes in 50% to
60% in patients with coronary heart disease
or acute myocardial infarction compared
with 7% to 12% in the controls. This study
did not take into account risk factors for
heart disease such as smoking, hyperten-
sion, or serum lipid levels. Subsequently,
several cross-sectional studies involving 46
to 461 study participants have shown that a
similar association of IgG antibodies against
C. pneumoniae with coronary artery disease
and carotid disease with adjusted odds ratios
of 1.6 to 2.6 after controlling for known risk
factors (68-72). Electron microscopy, PCR,
and immunochemical evidence of C.
pneumoniae in coronary arterial fatty
streaks and atheromatous plaques have also
been described (72,73).Vol. 2, No. 4—October-December 1996 Emerging Infectious Diseases 315
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Two more recent studies reported equivo-
cal findings. In one, C. pneumoniae was
detected in 79% of 90 coronary atherectomy
specimens from symptomatic patients by
direct immunofluorescence and was con-
firmed by electron microscopy. Only 4% of 24
control nonatherosclerotic coronary speci-
mens were positive for C. pneumoniae (74).
The 24 control samples included 12 from
heart transplant patients whose arteries
were damaged, but not by atherosclerosis.
The absence of C. pneumoniae in these tissue
samples argues against its role as a
passenger recruited to the site of injury in
macrophages. In the other study, C.
pneumoniae  was not detected in 58 coronary
atheroma specimens by culture, PCR, or
electron microscopy (75). The seroprevalence
of C. pneumoniae in 65 case-patients was not
different from that in 28 asymptomatic
controls. In fact, IgG titers were higher in
controls than in case-patients. Nonetheless,
data suggest that the association of C.
pneumoniae with atherosclerosis is consis-
tent and biologically plausible. Whether C.
pneumoniae is causally involved or is a
bystander trapped in the atherogenic process
is unclear.
The sustained IgA and IgG antibody
levels against C. pneumoniae in persons with
atherosclerosis suggest that chronic infec-
tion may be frequent after infection. The site
of colonization for a chronic C. pneumoniae
infection may be in the alveolar macrophages
of the lung. Thus the initial event in
atherogenesis may be the formation of the
fatty streak. Fatty streaks consist of lipid-
laden macrophages derived from blood
monocytes and T lymphocytes attracted to
the arterial subintima. Conversion of the
fatty streak to atheroma depends on many
factors, e.g., the proliferation and differen-
tiation of smooth muscle cells and fibro-
blasts. Chronic infection with C. pneumoniae
may result from organisms harbored in
macrophages trapped in the arterial wall.
Growth of C. pneumoniae in endothelial,
smooth muscle cells, and macrophages from
peripheral blood monocytes has been re-
ported (76). Injured blood vessels initiate
events that promote thrombosis and platelet
adhesion at the site of injury. These events in
turn promote atherosclerosis. Tissue injury
through C. pneumoniae-specific circulating
immune complexes in patients with chronic
heart disease may be an alternate mecha-
nism or compounding atherogenesis. The
idea that an infectious agent is involved in
the atherogenic process is not new, but the
role of C. pneumoniae in this process needs to
be defined.
Association with Asthma
The prevalence of asthma, an important
chronic respiratory disorder, has been
steadily increasing. Viral and Mycoplasma
pneumoniae infections have been implicated
in exacerbating the disease. The first
observations on the association of C.
pneumoniae infection with the exacerbation
of asthma were made in 1986 when wheezing
was associated with acute bronchitis due to
C. pneumoniae infection (8,77). Subsequent
studies showed that exacerbation of asthma
due to C. pneumoniae  infection may occur in
1% to 11% of respiratory infections in adults
as well as children. The mechanism underly-
ing the association is unclear. Preliminary
results in animal models suggest that C.
pneumoniae can produce persistent infection
and cause pulmonary inflammation, and
production of chlamydia-specific IgE anti-
bodies in children with reactive airway
disease has been demonstrated (78). A
possible scenario for this association is an
antigen-specific allergic reaction with the
release of pulmonary inflammatory media-
tors and recruitment of inflammatory cells to
the airways, causing airway epithelial
damage. Activated T lymphocytes and
cytokines appear to play a critical role as
mediators of persistent inflammation in
asthma. IL-4 is essential for B lymphocytes
class switching from IgG to IgE. In vitro
human IgE synthesis is reciprocally regu-
lated by IL-4 and interferon-gamma. Thus
cytokines from a Th
2 response to infection
would facilitate and promote IgE production.
Immunotherapy or glucocorticoid therapy
targeting CD4+ T cells may decrease the
proinflammatory role of these cells and
alleviate symptoms of asthma. The role of
persistent infection in the pathogenesis of
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viral infections, C. pneumoniae infections
can be eradicated through appropriate
antimicrobial therapy.
The hallmark of chlamydial infection is
that most persons infected have mild to no
apparent clinical disease and some have
severe disease. Asymptomatic infection not
only creates a problem in detecting cases for
disease control programs but also contrib-
utes to the development of long-term adverse
sequelae, such as scarring trachoma from
ocular C. trachomatis infection, pelvic
inflammatory disease, ectopic pregnancy,
and tubal factor infertility from genital C.
trachomatis infection. The recent availabil-
ity of effective single dose oral antimicrobial
therapy and sensitive molecular amplifica-
tion tests that allow the use of noninvasive
specimens for diagnosis and screening is
expected to have a major impact in reducing
the prevalence of disease in the next decade.
New information from cell biology as well as
data from observing the interaction of
chlamydiae with the host in terms of
metabolic requirements and immune evasion
strategies offer clues about the pathogenesis
of chlamydia infections and may eventually
lead to an effective vaccine. Sporadic
outbreaks of psittacosis continue to be
reported despite the use of medicated feed
and the screening of poultry. Recent reports
of C. psittaci in cats from breeding catteries
illustrate the potential of zoonotic diseases
transmissible to humans from pets other
than birds. Two new species of chlamydiae,
C. pneumoniae and C. pecorum, were desig-
nated in 1989 and 1992, respectively.
Clinical manifestations associated with C.
pneumoniae infection continue to emerge.
Possible links to chronic conditions, such as
atherosclerosis and asthma remain to be
elucidated. With the recent discovery of the
involvement of infectious agents in other
chronic conditions, it seems reasonable to
apply molecular tools for chlamydial detec-
tion to identify their potential involvement
in other etiologically undefined chronic
inflammatory conditions such as inflamma-
tory bowel disease and rheumatoid arthritis.
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the Division of Chlamydial and Mycoplasma
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diagnosis and pathogenesis of chlamydial infec-
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adverse ocular and reproductive sequelae in
human chlamydial infections.
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